MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Short Interest Up 144.9% in December

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) was the recipient of a large growth in short interest in the month of December. As of December 15th, there was short interest totaling 1,685,137 shares, a growth of 144.9% from the November 30th total of 687,986 shares. Approximately 6.7% of the shares of the stock are sold short. Based on an average daily volume of 1,479,960 shares, the short-interest ratio is currently 1.1 days. Based on an average daily volume of 1,479,960 shares, the short-interest ratio is currently 1.1 days. Approximately 6.7% of the shares of the stock are sold short.

Insider Activity

In other news, Director Ngar Yee Louie bought 81,699 shares of the stock in a transaction that occurred on Monday, December 22nd. The shares were bought at an average price of $1.22 per share, for a total transaction of $99,672.78. Following the purchase, the director owned 1,248,888 shares in the company, valued at $1,523,643.36. This represents a 7.00% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, Director Stan Smith purchased 57,189 shares of the business’s stock in a transaction on Monday, December 22nd. The stock was acquired at an average price of $1.22 per share, with a total value of $69,770.58. Following the purchase, the director directly owned 1,421,478 shares in the company, valued at $1,734,203.16. This represents a 4.19% increase in their position. The SEC filing for this purchase provides additional information. Insiders have bought 368,352 shares of company stock valued at $427,192 over the last 90 days. Company insiders own 32.32% of the company’s stock.

Institutional Investors Weigh In On MAIA Biotechnology

A number of hedge funds have recently made changes to their positions in MAIA. Geode Capital Management LLC raised its position in shares of MAIA Biotechnology by 3.6% during the 2nd quarter. Geode Capital Management LLC now owns 222,183 shares of the company’s stock valued at $400,000 after buying an additional 7,746 shares in the last quarter. Centerpoint Advisory Group bought a new stake in shares of MAIA Biotechnology in the 2nd quarter worth about $28,000. Marshall Wace LLP purchased a new position in shares of MAIA Biotechnology during the 2nd quarter worth about $29,000. Jane Street Group LLC purchased a new position in shares of MAIA Biotechnology during the 2nd quarter worth about $52,000. Finally, Centric Wealth Management grew its holdings in MAIA Biotechnology by 740.2% during the 2nd quarter. Centric Wealth Management now owns 573,398 shares of the company’s stock valued at $1,032,000 after purchasing an additional 505,150 shares during the last quarter. 5.65% of the stock is currently owned by hedge funds and other institutional investors.

MAIA Biotechnology Trading Up 6.1%

MAIA traded up $0.09 on Friday, hitting $1.57. 761,956 shares of the company’s stock traded hands, compared to its average volume of 977,358. The company’s 50 day simple moving average is $1.22 and its 200-day simple moving average is $1.50. MAIA Biotechnology has a one year low of $0.87 and a one year high of $2.74. The firm has a market cap of $58.14 million and a price-to-earnings ratio of -2.15.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last posted its quarterly earnings results on Friday, November 7th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.08). As a group, equities analysts anticipate that MAIA Biotechnology will post -1.3 EPS for the current fiscal year.

About MAIA Biotechnology

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.